John Oyler Sells 48,316 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 48,316 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $312.25, for a total transaction of $15,086,671.00. Following the transaction, the chief executive officer owned 9,180 shares in the company, valued at approximately $2,866,455. This trade represents a 84.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The stock was sold at an average price of $317.67, for a total value of $19,503,984.99.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Performance

ONC traded up $2.12 during trading on Tuesday, hitting $328.02. The company’s stock had a trading volume of 92,531 shares, compared to its average volume of 278,183. The business’s 50 day simple moving average is $292.10 and its 200-day simple moving average is $309.39. The firm has a market cap of $35.99 billion, a PE ratio of 73.35 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $253.95 and a one year high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the company. Guggenheim upped their price target on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Morgan Stanley reissued an “overweight” rating and issued a $395.00 target price on shares of BeOne Medicines in a report on Thursday, May 7th. Citizens Jmp reaffirmed a “market outperform” rating and set a $396.00 price target on shares of BeOne Medicines in a report on Wednesday, July 1st. Finally, Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Friday, July 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, BeOne Medicines currently has a consensus rating of “Moderate Buy” and an average target price of $394.00.

Hedge Funds Weigh In On BeOne Medicines

Several large investors have recently made changes to their positions in ONC. BNP Paribas Financial Markets raised its stake in BeOne Medicines by 100.6% during the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after purchasing an additional 97,244 shares during the period. SEB Asset Management AB purchased a new position in BeOne Medicines in the 1st quarter worth approximately $16,653,000. Capital International Sarl boosted its stake in BeOne Medicines by 2.7% in the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after purchasing an additional 3,956 shares during the period. Slow Capital Inc. grew its holdings in BeOne Medicines by 51.5% during the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock valued at $8,294,000 after buying an additional 9,280 shares in the last quarter. Finally, Capital International Investors grew its holdings in BeOne Medicines by 1.3% during the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after buying an additional 67,808 shares in the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.